Febuxostat is used as a long-term medication to treat gout due to high uric acid levels.
Febuxostat is a non-purine-selective inhibitor of xanthine oxidase that inhibits the enzyme by non-competitively blocking the molybdenum pterin center. The consequence of this inhibition is the reduction of production of uric acid.
Febuxostat has been shown to be more effective than standard doses of Allopurinol.
SMB’s product offers better compliance to national guidelines due to the use of our Divule® technology which provides a flexible dosing regimen ranging from 40mg to 120mg per intake if required.
Our product is proposed in capsule shaped divisible tablet containing 80 mg of Febuxostat
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy Policy